The abstract is read at the publisher; the summary is JClub's.
The 2026 European Association of Urology guidelines for nonmuscle-invasive bladder cancer (TaT1 and CIS) add risk, prognostic, and treatment tables plus new BCG-unresponsive and BCG-NAïve strategies.
- Why it matters: Clinicians need practical, evidence-based guidance to manage NMIBC, where outcomes depend on accurate diagnosis, risk stratification, and appropriate follow-up decisions.
- What they did: The update was built by structured literature assessment using MEDLINE, EMBASE, and the Cochrane Library, with recommendation strength based on trade-offs, evidence quality, and patient values.
- The result: The guideline summary emphasizes thorough diagnosis, risk-based treatment, and follow-up, and introduces tools for urinary marker surveillance, immune checkpoint inhibitor use in selected BCG-NAïve high/very high-risk patients, and pragmatic de-intensification.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.